Anti-MERS-CoV Convalescent Plasma Therapy

Phase 2

Withdrawn

• Conditions: Respiratory Distress Syndrome (& [Hyaline Membrane Disease])
• Interventions: Biological: Convalescent plasma

• Registration Number: NCT02190799
• Lead Sponsor: King Abdullah International Medical Research Center

Brief Summary

Since the first report of the Middle East Respiratory Syndrome Corona virus (MERS- CoV) in September 2012, more than 800 cases have been reported to the World Health Organization (WHO) with substantial mortality.

Detailed Description

World knowledge about this virus is accumulating but data about the clinical presentations of infected patients and common treatments, including ribavirin, interferon and methylprednisolone, lack evidence. Although drugs with anti- coronavirus (CoV) activities have been identified, as yet no anti- MERs- CoV drug has been approved and a vaccine has yet to be developed. Previous reports on other viral infections including SARS have suggested that convalescent plasma or serum is effective where no other treatment is available or in an emergency. A recently completed systematic review and meta-analysis by the University of Nottingham - World Health Organization Collaborating Center indicates that convalescent plasma therapy may be the most promising near-term therapy patients with for MERS- CoV infection. In this study, investigators will study the pharmacokinetics of immunoglobulin in response to convalescent plasma administration in order to inform a much larger study which will investigate the efficacy of convalescent plasma. Plasma will be collected from patients who recently recovered from MERS-CoV, Health Care Workers who had potential exposure and are tested for anti MERS-CoV serology and RT-PCR after obtaining their consent. This convalescent plasma will be stored in the blood bank as per their policies and procedures. Patients with MERS-CoV positive after meeting the eligibility criteria will receive 2 units of convalescent plasma . Clinical data as well as the standard laboratory studies will be collected at baseline, 30 mins after first dose, 30 mins after second dose, day 1, 3, 7, 14, 28 of hospital stay after enrollment.

Study Timeline

• Study Start: 2014-05
• Study First Submitted: 2014-06-12
• Study First Submitted QC: 2014-07-13
• Study First Posted: 2014-07-15
• Primary Completion: 2016-05
• Study Completion: 2016-11
• Status Verified: 2018-11
• Last Update Submitted: 2018-11-19
• Last Update Posted: 2018-11-21

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Age greater than or equal to 14 years of age
• Inpatients who are MERS-COV positive (by PCR)
• Willingness to have blood, respiratory and urine samples obtained and stored for subsequent analysis.

Read More

Exclusion Criteria

• Clinical evidence (in the judgment of the site investigator) that the etiology of illness is primarily not MERS-CoV in origin.
• History of allergic reaction to blood or plasma products (as judged by the investigator)
• Known IgA deficiency
• Medical conditions in which receipt of 500mL volume may be detrimental to the patient (e.g., decompensated congestive heart failure)
• Females who are pregnant or breast feeding.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Convalescent plasma	Convalescent plasma	Enrolled patients will receive 2 units of the convalescent plasma after meeting the eligibility criteria

Primary Outcome Measures

Name	Time	Method
Hospital mortality	Death in the Hospital (ICU or ward) before or at 6 months after enrollment	Hospital mortality will be death in the ICU during the same hospital admission

Secondary Outcome Measures

Name	Time	Method
ICU Length of Stay	Number of days in ICU with an average expected duration of 10 days.	Number of calendar days between admission and final discharge from ICU.
Anti-MERS-CoV antibodies	Serial levels in the first 28 days of enrollment	anti-MERS-CoV antibody level before and after administration of CP.
Viral load in tracheal aspirate	Serial levels in the first 28 days of enrollment	viral clearance from all sampled sites by day 3 after administration of CP
Inflammatory markers,	Serial levels in the first 28 days of enrollment	Epidermal Growth Factor (EGF), Eotaxin, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interferon(IFN)-γ, IFN-a2, Interleukin (IL)-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IL-1ra, IL-1a, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, Interferon gamma-induced protein (IP)-10, Monocyte Chemotactic Protein (MCP)-1, Macrophage Inflammatory Protein (MIP)-1a, MIP-1β, Tumor Necrosis Factor-α (TNF-a), TNF-β, Vascular Endothelial Growth Factor (VEGF)
ICU mortality	Death in the ICU at or after 90 days of enrollment	Death in the ICU during the same hospital admission.
Duration of Mechanical Ventilation	Number of days of mechanical ventilation with an expected average duration of 8 days	Number of calendar days between start and final liberation from mechanical ventilation.

Trial Locations

Locations (1)

Intensive Care Unit, King Abdulaziz Medical City; 🇸🇦 Riyadh,, Saudi Arabia